Global pharma manufacturing companies like
Pfizer, Novartis is facing an unprecedented crisis in terms of sales growth,
profitability and discovery of new drugs for the last some years now. With
increasing rate of patent expiry of several blockbusters and reduced spending
on research, top multinational drug companies are facing a rather gloomy future
in the years to come.
- Controlling prices of essential
drugs has been a challenging task for several years in India as the
pharmaceutical companies have not been cooperating with the government to
achieve this basic social objective.
- Online selling of prescription
drugs to overseas customers by a group of traders from India without drug
licenses and prescriptions is posing a big challenge to the regulatory
authorities in the country. This fast growing illegal trade of medicines from
India can thus seriously affect the reputation of the country as India is
already major supplier of quality generics to the world markets.
- India has been witnessing the
trend of steadily increasing import of APIs, intermediates and excipients from
China at very low prices for some years now. The government was concerned as
these imports were posing a threat to domestic API industry.
- The use of medical devices for
various health conditions has increased considerably during the last ten years
in the country. But there is no competent authority to check the quality and
prices of medical devices and that situation has led to marketing of
substandard products getting into the market at exorbitant prices.
- The need for centralizing drug
licensing was felt as the state drug authorities have been issuing licenses
without any scrutiny of applications resulting in circulation of thousands of
irrational and harmful combination drugs in the market.
- Steady decline in the export of pharmaceuticals especially to the big markets like the US and Europe during last two years is yet another issue of great concern.
Pharma Manufacturing Companies in Ahmedabad | International Pharma Companies in India
0 comments:
Post a Comment